TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Continuous Abstinence Rate (CAR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in number of minutes per day of light to strenuous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of minutes per day of bouts of sedentary behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal of intraoral pathogenic bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hb level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and tolerability of PEGPH20
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy achievement
Endpoint domain: Mortality/survival
Primary endpoint: Mean Change of Morisky Medication Adherence Scale -8 (MMAS-8) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in mAIS parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in specific rating scales
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Significant myocardial retention of 68Ga-DOTATOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Modified Oswestry Low Back Pain Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Oral feeding efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard uptake value (SUV) of 68Ga-DOTANOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference of quantitative changes in repigmented area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of episodes of clinical malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Route of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients With Feeding Tube Dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cardiovagal Baroreflex Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in plasma phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ß-cell Secretory Capacity at 6 Months (μU/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in ß-cell Secretory Capacity at 6 Months (pg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Use of cancer screening and preventive services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reactive hyperemic index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mean Pain Due to MS NRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With at Least 30% Improvement in NRS Pain Score From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection with influenza virus
Endpoint domain: Adverse events/effects
Primary endpoint: Amblyopia Risk Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average worst AF-related pain associated with defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self reported pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Immunohistochemistry + PCR results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse in Atopic Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pitch strength of Brainstem EEG responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reaction time in millisecond for speech perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pitch tracking accuracy of Brainstem EEG responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in SPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of Detecting Epileptiform Discharges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: plaque acidogenicity (pH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to successfully intubate the trachea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Use of the IUD for Contraception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients With Treatment Related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Triamcinolone acetonide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic triglyceride synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adipose tissue triglyceride synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gingival fluid production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time and dose of propofol at loss of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with >= 75% adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of weight (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of fever and signs of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Best Objective Response Rate (BORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Aerobic Colony Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recall period for LUTS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Drinking Days (PDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants having Serious and Non-serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with 80% Adherence to Safflower Oil Pretzels
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum exposure level of CT-044
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Pharmacokinetic Concentration of CT-044
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Pharmacokinetic Concentration of CT-044
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Fever
Endpoint domain: Adverse events/effects
Primary endpoint: Graft Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Acute Rejection Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Volumetric flow of cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target tumor response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in serum concentration of GH and IGF1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in function of the foot - angle ankle joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Function of the hand - Dreiser functional index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Identification of patients at high risk of developing hereditary colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: First psychosis disorder diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic adherence to CPAP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consultation cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient satisfaction: questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain During Normal Activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients requiring stent replacements
Endpoint domain: Adverse events/effects
Primary endpoint: Percent frequency liver toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Maximal oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: psychological response to daily self-weighing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Dysmenorrheic Pain VAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days With Dysmenorrheic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LTD4 PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Timing of Endogenous Melatonin Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Acetylcholine induced vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Diagnostic result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: enhanced satisfaction with the decision
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: enhanced adherence to medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Grade 3 to 5 cytokine release syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline GSCI score at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification rate of sentinel nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value associated with subareolar injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiopulmonary death
Endpoint domain: Mortality/survival
Primary endpoint: Clinical right heart failure hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive Predictive Value (PPV) of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: efficacy assessed with the Montgomery-Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: efficacy assessed with the Hamilton Rating scale for Depression (HAMD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number and severity of ocular and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing serious and drug-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Activity of combination treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Review of Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant changes in biochemical and haematological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinically significant ECG changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of serum s100β
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of serum NSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of serum GFAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of serum cognitive functions and delirium status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CgA level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in activation of the pain processing networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients alive without major amputation
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients alive without critical limb ischemia
Endpoint domain: Mortality/survival
Primary endpoint: Time to perform laparoscopic nephrectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Days to patient discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Clinical Global Impression- Severity Scale (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Short Form Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Short Musculoskeletal Function Assessment (SMFA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in AOFAS Hindfoot Scale questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Foot and Ankle Disability Index (FADI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to loss of androgen-dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline compound score of standardized neuropsychological test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hearing Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants self-reporting receipt of Pap test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence and prevalence of clinically relevant cardiac arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: haematological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Antibiotic compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counseling efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reinforcement value (eGetgoing)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reinforcement value (on-site)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence or change in morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in portal circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: whole body galactose oxidative capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalized F3-F2 Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific survival free of total laryngectomy
Endpoint domain: Mortality/survival
Primary endpoint: muscle recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants Achieving MCID in HAQ-DI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental frailty
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in quadriceps motor force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual Analogue Scale (VAS) score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECOG Performance status (PS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PET Uptake/Standardized uptake value ratio (SUVR) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of functional outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated plasma AUC0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Fractional Synthesis Rate (FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Measured by the Minnesota Living With Heart Failure Questionnaire-total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Death from any cause at 8 years
Endpoint domain: Mortality/survival
Primary endpoint: Cytolytic T lymphocyte response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicity of the combination peptide and immunological adjuvants
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical recurrence of varicose veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Event-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Shoulder pain-related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number and severity of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Serum Vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diameter of lymphedema of neck with face
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Questionnaire-Head and Neck 35
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Head and neck external lymphedema rating scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patterson larynx pharynx internal edema scale outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orthostatic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recommended phase II dose
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Positive and Negative Syndrome Scale total score (PANSS T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of cadmium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasticity measured by Modified Ashworth scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Bacterial load of six main periodontal pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of six main periodontal pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum AUC0-last of Rituximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum AUC0-inf of Rituximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Cmax of Rituximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of DAS28 (CRP) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tapping Task Performance Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bold Signal Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Sleep Spindles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma uric acid AUC0-96
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median duration of therapy until control of plasma uric acid values to <8.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients developing hypertension requiring therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Morphine Equivalents Used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Embryo mitochondrial DNA (mtDNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes